<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23381">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01913613</url>
  </required_header>
  <id_info>
    <org_study_id>2013-01</org_study_id>
    <nct_id>NCT01913613</nct_id>
  </id_info>
  <brief_title>REDUCE LAP-HF TRIAL: A Study to Evaluate the DC Devices, Inc. IASD™ System II to REDUCE Elevated Left Atrial Pressure in Patients With Heart Failure</brief_title>
  <acronym>REDUCE LAP-HF</acronym>
  <official_title>REDUCE LAP-HF TRIAL: A Study to Evaluate the DC Devices, Inc. IASD™ System II to REDUCE Elevated Left Atrial Pressure in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DC Devices, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DC Devices, Inc.</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Austria: Austrian Medicines and Medical Devices Agency</authority>
    <authority>Austria: Ethikkommission</authority>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <authority>Denmark: Ethics Committee</authority>
    <authority>France: The Commission nationale de l’informatique et des libertés</authority>
    <authority>Germany: Ethics Commission</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Germany: Federal Office for Radiation Protection</authority>
    <authority>Greece: Ethics Committee</authority>
    <authority>Greece: National Organization of Medicines</authority>
    <authority>Netherlands: Dutch Health Care Inspectorate</authority>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <authority>New Zealand: Medsafe</authority>
    <authority>New Zealand: Ethics Committee</authority>
    <authority>Poland: Ethics Committee</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical study is to evaluate the safety and performance of the IASD
      System II in the treatment of heart failure patients with elevated left atrial pressure, who
      remain symptomatic despite appropriate medical management.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>MACCE</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>subjects who experience major adverse cardiac and cerebrovascular events (MACCE) defined as death, stroke, MI; or subjects who experience a systemic embolic event (excluding pulmonary thromboembolism)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with the IASD device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IASD</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Chronic symptomatic Heart Failure (HF) documented by one or more of the following:

               1. New York Heart Association (NYHA) Class II/III/ambulatory class IV symptoms
                  (Paroxysmal nocturnal dyspnea, Orthopnea, Dyspnea on mild or moderate exertion)
                  at screening visit; or signs (Any rales post cough, Chest x-ray demonstrating
                  pulmonary congestion,) within past 12 months;

               2. One hospital admission for which HF was a major component of the hospitalization
                  within the 12 months prior to study entry (transient heart failure in the
                  context of myocardial infarction does not qualify);

               3. Chronic or intermittent treatment with a loop diuretic

          2. Age ≥ 40 years old

          3. Left ventricular ejection fraction (obtained by echocardiography) ≥ 40%

          4. Elevated left ventricular filling pressures with a gradient compared to CVP
             documented by :

               1. PCWP or LVEDP at rest  ≥ 15 mmHg, and greater than CVP, OR

               2. PCWP during supine bike exercise ≥ 25mm Hg, and CVP &lt; 20 mm Hg

        Key Exclusion Criteria:

        3. Severe heart failure defined as:

          1. ACC/AHA/ESC Stage D heart failure, Non-ambulatory NYHA Class IV HF;

          2. Fick Cardiac Index  &lt; 2.2 L/min/m2

          3. Requiring inotropic infusion (continuous or intermittent) within the past 6 months

          4. Patient is on the cardiac transplant waiting list 4. Inability to perform 6 Minute
             Walk Test 5. Known significant coronary artery disease (stenosis &gt;70%) 6. History of
             stroke, transient ischemic attack (TIA), deep vein thrombosis (DVT), or pulmonary
             emboli within the past 6 months 7. Known severe carotid artery stenosis (&gt; 70%) 8.
             Presence of significant valve disease defined by echocardiography as: a) Mitral valve
             regurgitation defined as grade &gt;2+ MR b) Tricuspid valve regurgitation defined as
             grade  ≥ 2+ TR; c) Aortic valve disease defined as ≥ 2+ AR or moderate AS
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jan Komtebedde, DVM</last_name>
    <email>jkomtebedde@dcdevicesinc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Kulis</last_name>
    <email>akulis@dcdevicesinc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Homolka Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 13, 2014</lastchanged_date>
  <firstreceived_date>July 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
